Focal therapy of localised prostate cancer by vascular targeted photodynamic therapy with WST-11 (TOOKAD® Soluble) Academic Article uri icon

Overview

MeSH Major

  • Apoptosis
  • Inflammation
  • NF-kappa B
  • Phosphotransferases (Alcohol Group Acceptor)
  • Skin
  • TNF Receptor-Associated Factor 2

abstract

  • Photodynamic therapy (PDT) is the activation of a light sensitive compound within tissues to produce a desired treatment effect, including apoptosis and necrosis, and is a modality effectively used in a variety of benign and malignant conditions for the purpose of tissue ablation. TOOKAD® (T or WST-09) and TOOKAD Soluble (TS or WST-11), two derivatives of the photosynthetic pigment bacteriochlorophyll (Bchl), represent a new generation of photosensitizers and a new paradigm in PDT for cancer treatment. Studies of the mechanism of action, optimisation of treatment parameters, and therapeutic efficacy have included rigorous laboratory research, preclinical models and a series of prospectively designed clinical investigations demonstrating the great promise for this class of therapeutics in the treatment of human malignancies. This short review briefly describes the principles of T/TS vascular targeted photodynamic therapy and its application in the context of localised prostate cancer treatment as a form of focal therapy. © Touch Medical Media 2012.

publication date

  • December 2012

Research

keywords

  • Academic Article

Additional Document Info

start page

  • 106

end page

  • 108

volume

  • 7

number

  • 2